Philip A Barber Selected Research

Leukoaraiosis

1/2008

Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philip A Barber Research Topics

Disease

19	Stroke (Strokes) 10/2020 - 01/2002
10	Ischemic Stroke 12/2020 - 01/2002
7	Ischemia 12/2020 - 07/2004
6	Infarction (Infarctions) 12/2020 - 05/2013
5	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 12/2015
5	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 12/2015 - 01/2003
3	Cognitive Dysfunction 01/2022 - 01/2018
3	Atrophy 12/2021 - 01/2018
3	Hypothermia 12/2015 - 01/2003
2	Vascular Diseases (Vascular Disease) 08/2021 - 01/2018
2	Edema (Dropsy) 01/2020 - 01/2012
2	Brain Ischemia (Cerebral Ischemia) 01/2012 - 02/2010
1	Disease Progression 12/2021
1	Gliosis 12/2021
1	Sudden Hearing Loss (Sudden Deafness) 11/2021
1	Myocardial Infarction 10/2020
1	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 01/2018
1	Transient Ischemic Attack 01/2018
1	Brain Infarction 03/2016
1	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 12/2015
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 03/2015
1	Leukoaraiosis 01/2008
1	Hemorrhage 01/2007
1	Diabetes Complications 08/2006

Drug/Important Bio-Agent (IBA)

6	Tissue Plasminogen Activator (Alteplase)FDA Link 03/2016 - 01/2002
4	Amyloid (Amyloid Fibrils)IBA 01/2022 - 12/2015
3	Gadolinium DTPA (Magnevist)FDA Link 09/2011 - 07/2004
2	Proteins (Proteins, Gene)FDA Link 12/2021 - 06/2012
2	Neuroprotective AgentsIBA 01/2020 - 05/2013
2	Biomarkers (Surrogate Marker)IBA 12/2018 - 01/2018
2	Immunoglobulin G (IgG)IBA 12/2015 - 02/2010
2	ResveratrolIBA 05/2013 - 01/2012
2	PolyphenolsIBA 05/2013 - 01/2012
2	salicylhydroxamic acid (SHAM)IBA 06/2012 - 11/2005
2	Glucose (Dextrose)FDA LinkGeneric 01/2012 - 01/2007
2	Contrast MediaIBA 02/2010 - 07/2004
1	Formaldehyde (Formol)FDA Link 01/2022
1	Protein AggregatesIBA 12/2021
1	IronIBA 01/2018
1	Biological ProductsIBA 03/2016
1	Flavin-Adenine Dinucleotide (FAD)IBA 12/2015
1	FibrinIBA 03/2015
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 03/2015
1	Pharmaceutical PreparationsIBA 03/2015
1	Tenecteplase FDA Link 03/2015
1	Adenosine Triphosphate (ATP)IBA 05/2013
1	NAD (NADH)IBA 05/2013
1	Sirtuin 1IBA 05/2013
1	Matrix Metalloproteinases (MMPs)IBA 06/2012
1	Oxygen (Dioxygen)IBA 01/2012
1	Acetic Acid (Vinegar)FDA LinkGeneric 09/2011
1	Claudin-5IBA 09/2011
1	OccludinIBA 09/2011
1	diethylenetriamineIBA 09/2011
1	PENTAIBA 09/2011
1	GadoliniumIBA 09/2011
1	P-SelectinIBA 02/2010
1	Fluorescein-5-isothiocyanate (FITC)IBA 02/2010
1	Receptor for Advanced Glycation End ProductsIBA 08/2006
1	E-SelectinIBA 07/2004
1	Sialyl Lewis X AntigenIBA 07/2004

Therapy/Procedure

13	Therapeutics 12/2020 - 01/2002
2	Secondary Prevention 08/2021 - 01/2018
1	Thrombectomy 11/2021
1	Aftercare (After-Treatment) 12/2016
1	Time-to-Treatment 12/2015
1	Rewarming 12/2015
1	Length of Stay 01/2009
1	Thrombolytic Therapy 02/2004
1	Decompression 01/2003